VIT-WAGNER
Regimen
- Experimental
- Temozolomide + intravenous irinotecan (no vincristine in this original pilot — VIT triplet evolved later)
- Control
- None
Population
Children/AYA with advanced Ewing sarcoma family of tumors after >=1 prior regimen
Key finding
Original pediatric signal that irinotecan + temozolomide is active in relapsed Ewing. The vincristine was added empirically by later groups, producing the VIT triplet. This small phase 2 is the historical seed of the entire VIT narrative.
Source: PMID 16317751